Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- PMID: 27433846
- PMCID: PMC4986616
- DOI: 10.1056/NEJMoa1603144
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Abstract
Background: Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.
Methods: We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis. We isolated germline DNA and used multiplex sequencing assays to assess mutations in 20 DNA-repair genes associated with autosomal dominant cancer-predisposition syndromes.
Results: A total of 84 germline DNA-repair gene mutations that were presumed to be deleterious were identified in 82 men (11.8%); mutations were found in 16 genes, including BRCA2 (37 men [5.3%]), ATM (11 [1.6%]), CHEK2 (10 [1.9% of 534 men with data]), BRCA1 (6 [0.9%]), RAD51D (3 [0.4%]), and PALB2 (3 [0.4%]). Mutation frequencies did not differ according to whether a family history of prostate cancer was present or according to age at diagnosis. Overall, the frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer (P<0.001), including men with high-risk disease, and the prevalence of 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis (P<0.001).
Conclusions: In our multicenter study, the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer was 11.8%, which was significantly higher than the incidence among men with localized prostate cancer. The frequencies of germline mutations in DNA-repair genes among men with metastatic disease did not differ significantly according to age at diagnosis or family history of prostate cancer. (Funded by Stand Up To Cancer and others.).
Figures
Comment in
-
Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Eur Urol. 2016 Oct;70(4):703-704. doi: 10.1016/j.eururo.2016.07.039. Epub 2016 Jul 29. Eur Urol. 2016. PMID: 27481180 No abstract available.
-
Should we Perform Genetic Testing on Men with Metastatic Prostate Cancer?Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e92. doi: 10.1016/j.clon.2016.10.004. Epub 2016 Oct 25. Clin Oncol (R Coll Radiol). 2017. PMID: 27789128 No abstract available.
-
DNA-Repair Gene Mutations in Metastatic Prostate Cancer.N Engl J Med. 2016 Nov 3;375(18):1804-5. doi: 10.1056/NEJMc1611137. N Engl J Med. 2016. PMID: 27806229 No abstract available.
-
DNA-Repair Gene Mutations in Metastatic Prostate Cancer.N Engl J Med. 2016 Nov 3;375(18):1802-1803. doi: 10.1056/NEJMc1611137. N Engl J Med. 2016. PMID: 27806230 Free PMC article. No abstract available.
-
DNA-Repair Gene Mutations in Metastatic Prostate Cancer.N Engl J Med. 2016 Nov 3;375(18):1803. doi: 10.1056/NEJMc1611137. N Engl J Med. 2016. PMID: 27806231 No abstract available.
-
Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.Eur Urol. 2017 Apr;71(4):692. doi: 10.1016/j.eururo.2016.12.018. Epub 2017 Jan 6. Eur Urol. 2017. PMID: 28065537 No abstract available.
-
Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.J Urol. 2017 Feb;197(2):399-400. doi: 10.1016/j.juro.2016.11.070. Epub 2016 Nov 16. J Urol. 2017. PMID: 28093145 No abstract available.
-
DNA-Repair Gene Mutations in Metastatic Prostate Cancer.N Engl J Med. 2016 Nov 3;375(18):1803-4. doi: 10.1056/NEJMc1611137. N Engl J Med. 2016. PMID: 28106975 No abstract available.
-
Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.Urol Oncol. 2017 Aug;35(8):536-537. doi: 10.1016/j.urolonc.2017.05.012. Epub 2017 Jun 13. Urol Oncol. 2017. PMID: 28623070
-
Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.Cancer Biol Ther. 2017 Aug 3;18(8):545-546. doi: 10.1080/15384047.2017.1345398. Epub 2017 Jul 5. Cancer Biol Ther. 2017. PMID: 28678600 Free PMC article.
-
Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.Urol Oncol. 2017 Sep;35(9):575-576. doi: 10.1016/j.urolonc.2017.07.006. Epub 2017 Aug 5. Urol Oncol. 2017. PMID: 28789927
Similar articles
-
Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.Urol Oncol. 2017 Sep;35(9):575-576. doi: 10.1016/j.urolonc.2017.07.006. Epub 2017 Aug 5. Urol Oncol. 2017. PMID: 28789927
-
Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.Urol Oncol. 2017 Aug;35(8):536-537. doi: 10.1016/j.urolonc.2017.05.012. Epub 2017 Jun 13. Urol Oncol. 2017. PMID: 28623070
-
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25. Prostate. 2018. PMID: 29368341 Free PMC article.
-
Genetically Informed Prostate Cancer Treatment for Metastatic Disease.Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10. Urol Clin North Am. 2021. PMID: 34210491 Review.
-
Bringing Prostate Cancer Germline Genetics into Clinical Practice.J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8. J Urol. 2019. PMID: 30730411 Review.
Cited by
-
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.BJC Rep. 2024 Feb 15;2(1):15. doi: 10.1038/s44276-023-00024-8. BJC Rep. 2024. PMID: 39516637 Free PMC article.
-
Overcoming barriers to prostate cancer genetic testing: who, when, and how.Prostate Cancer Prostatic Dis. 2024 Nov 5. doi: 10.1038/s41391-024-00916-x. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39501079 No abstract available.
-
USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer.Cell Death Dis. 2024 Nov 5;15(11):790. doi: 10.1038/s41419-024-07117-3. Cell Death Dis. 2024. PMID: 39500888 Free PMC article.
-
PARP inhibitors in prostate cancer: clinical applications.Mol Biol Rep. 2024 Oct 30;51(1):1103. doi: 10.1007/s11033-024-10034-5. Mol Biol Rep. 2024. PMID: 39476131 Review.
-
Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer.BMC Cancer. 2024 Oct 25;24(1):1319. doi: 10.1186/s12885-024-13045-4. BMC Cancer. 2024. PMID: 39455978 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
- R01 CA193837/CA/NCI NIH HHS/United States
- P50CA92629/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- P50 CA092629/CA/NCI NIH HHS/United States
- P50CA097186/CA/NCI NIH HHS/United States
- 17528/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 CA155169/CA/NCI NIH HHS/United States
- R01 CA116337/CA/NCI NIH HHS/United States
- T32 GM007266/GM/NIGMS NIH HHS/United States
- 15007/CRUK_/Cancer Research UK/United Kingdom
- PC140799/PC/NCI NIH HHS/United States
- MR/M003272/1/MRC_/Medical Research Council/United Kingdom
- P50 CA180995/CA/NCI NIH HHS/United States
- P50 CA097186/CA/NCI NIH HHS/United States
- PC131820/PC/NCI NIH HHS/United States
- R01 CA175716/CA/NCI NIH HHS/United States
- K08 CA188615/CA/NCI NIH HHS/United States
- R01CA116337/CA/NCI NIH HHS/United States
- P30CA008748/CA/NCI NIH HHS/United States
- R35 CA197458/CA/NCI NIH HHS/United States
- 1K08CA188615/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous